Time for a change in breast cancer therapy?
Taken together, recent studies make a powerful case for the licensing of aromatase inhibitors in the adjuvant setting, offering an alternative to tamoxifen which has long been the gold standard in breast cancer therapy in the prevention of recurrence.
Cameron
David
D
Edinburgh University, Western General Hospital, Edinburgh EH4 2XU.
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D005260:Female; D005544:Forecasting; D006801:Humans; D017698:Postmenopause; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal